Summary & Overview
CPT 68540: Excision of Lacrimal Gland Tumor
CPT code 68540 denotes surgical excision of a lacrimal gland tumor, a procedure aimed at removing obstructing or potentially neoplastic tissue and providing a specimen for diagnostic analysis. This code captures a targeted oculoplastic surgical service that can impact patient vision, tear production, and oncologic management. Nationally, accurate coding for lacrimal gland excision matters for claims integrity, appropriate reimbursement, clinical documentation, and tracking surgical trends in ophthalmic oncology.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical sites of service (hospital operating room and ambulatory surgery centers), and the service type (surgical excision with specimen submission for pathology). The publication summarizes common billing practices and documentation elements relevant to this procedure and highlights typical modifiers used in surgical coding when applicable.
The report is intended to inform billing, coding, and clinical staff about the procedural intent and service setting associated with 68540, and to provide a foundation for reviewing benchmarks, policy updates, and payer-specific coverage considerations. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 68540 describes the surgical excision of a tumor from the lacrimal gland. The procedure is performed to remove an obstruction or mass in the lacrimal gland, prevent further complications, and obtain tissue for diagnostic laboratory analysis.
-
Service type: Surgical excision of lacrimal gland tumor
-
Typical site of service: Hospital operating room or ambulatory surgery center
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient presents with progressive swelling and discomfort in the superolateral orbit with occasional tearing and a palpable mass near the lacrimal gland. Ophthalmologic examination and orbital imaging (CT or MRI) show a well-circumscribed lacrimal gland mass suspicious for a benign or low-grade malignant neoplasm causing lacrimal duct obstruction. The oculoplastic surgeon schedules an excision of the lacrimal gland tumor under monitored anesthesia care or general anesthesia. Intraoperative steps include conjunctival or lateral orbitotomy exposure, careful dissection to excise the lesion with margin control, hemostasis, and specimen submission to pathology for diagnostic analysis. Postoperative workflow includes observation in the PACU, topical and/or systemic antibiotics and anti-inflammatory medications as indicated, pathology result review, and follow-up visits to monitor for wound healing, recurrence, or orbital/ocular complications.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the surgeon’s professional portion separated from a global service (rare for operative excision where global includes professional and technical). |
50 |